ApoE Lipidation as a Therapeutic Target in Alzheimer’s Disease
Apolipoprotein E (<i>APOE</i>) is the major cholesterol carrier in the brain, affecting various normal cellular processes including neuronal growth, repair and remodeling of membranes, synaptogenesis, clearance and degradation of amyloid β (Aβ) and neuroinflammation. In humans, the <i...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-09-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/21/17/6336 |
| _version_ | 1797554931820920832 |
|---|---|
| author | Maria Fe Lanfranco Christi Anne Ng G. William Rebeck |
| author_facet | Maria Fe Lanfranco Christi Anne Ng G. William Rebeck |
| author_sort | Maria Fe Lanfranco |
| collection | DOAJ |
| description | Apolipoprotein E (<i>APOE</i>) is the major cholesterol carrier in the brain, affecting various normal cellular processes including neuronal growth, repair and remodeling of membranes, synaptogenesis, clearance and degradation of amyloid β (Aβ) and neuroinflammation. In humans, the <i>APOE</i> gene has three common allelic variants, termed E2, E3, and E4. <i>APOE4</i> is considered the strongest genetic risk factor for Alzheimer’s disease (AD), whereas <i>APOE2</i> is neuroprotective. To perform its normal functions, apoE must be secreted and properly lipidated, a process influenced by the structural differences associated with apoE isoforms. Here we highlight the importance of lipidated apoE as well as the <i>APOE</i>-lipidation targeted therapeutic approaches that have the potential to correct or prevent neurodegeneration. Many of these approaches have been validated using diverse cellular and animal models. Overall, there is great potential to improve the lipidated state of apoE with the goal of ameliorating <i>APOE</i>-associated central nervous system impairments. |
| first_indexed | 2024-03-10T16:40:06Z |
| format | Article |
| id | doaj.art-c6b79fe1aed64983b39ba7288f6a5f84 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T16:40:06Z |
| publishDate | 2020-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-c6b79fe1aed64983b39ba7288f6a5f842023-11-20T12:08:05ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672020-09-012117633610.3390/ijms21176336ApoE Lipidation as a Therapeutic Target in Alzheimer’s DiseaseMaria Fe Lanfranco0Christi Anne Ng1G. William Rebeck2Department of Neuroscience, Georgetown University Medical Center, 3970 Reservoir Road NW, Washington, DC 20057, USADepartment of Neuroscience, Georgetown University Medical Center, 3970 Reservoir Road NW, Washington, DC 20057, USADepartment of Neuroscience, Georgetown University Medical Center, 3970 Reservoir Road NW, Washington, DC 20057, USAApolipoprotein E (<i>APOE</i>) is the major cholesterol carrier in the brain, affecting various normal cellular processes including neuronal growth, repair and remodeling of membranes, synaptogenesis, clearance and degradation of amyloid β (Aβ) and neuroinflammation. In humans, the <i>APOE</i> gene has three common allelic variants, termed E2, E3, and E4. <i>APOE4</i> is considered the strongest genetic risk factor for Alzheimer’s disease (AD), whereas <i>APOE2</i> is neuroprotective. To perform its normal functions, apoE must be secreted and properly lipidated, a process influenced by the structural differences associated with apoE isoforms. Here we highlight the importance of lipidated apoE as well as the <i>APOE</i>-lipidation targeted therapeutic approaches that have the potential to correct or prevent neurodegeneration. Many of these approaches have been validated using diverse cellular and animal models. Overall, there is great potential to improve the lipidated state of apoE with the goal of ameliorating <i>APOE</i>-associated central nervous system impairments. https://www.mdpi.com/1422-0067/21/17/6336apolipoprotein Echolesterollipid homeostasisneurodegeneration |
| spellingShingle | Maria Fe Lanfranco Christi Anne Ng G. William Rebeck ApoE Lipidation as a Therapeutic Target in Alzheimer’s Disease International Journal of Molecular Sciences apolipoprotein E cholesterol lipid homeostasis neurodegeneration |
| title | ApoE Lipidation as a Therapeutic Target in Alzheimer’s Disease |
| title_full | ApoE Lipidation as a Therapeutic Target in Alzheimer’s Disease |
| title_fullStr | ApoE Lipidation as a Therapeutic Target in Alzheimer’s Disease |
| title_full_unstemmed | ApoE Lipidation as a Therapeutic Target in Alzheimer’s Disease |
| title_short | ApoE Lipidation as a Therapeutic Target in Alzheimer’s Disease |
| title_sort | apoe lipidation as a therapeutic target in alzheimer s disease |
| topic | apolipoprotein E cholesterol lipid homeostasis neurodegeneration |
| url | https://www.mdpi.com/1422-0067/21/17/6336 |
| work_keys_str_mv | AT mariafelanfranco apoelipidationasatherapeutictargetinalzheimersdisease AT christianneng apoelipidationasatherapeutictargetinalzheimersdisease AT gwilliamrebeck apoelipidationasatherapeutictargetinalzheimersdisease |